β-Adrenoceptor
antagonists boast a 50-year use for symptomatic
control in numerous cardiovascular diseases. One might expect highly
selective antagonists are available for the human β-adrenoceptor
subtype involved in these diseases, yet few truly β1-selective molecules exist. To address this clinical need, we re-evaluated
LK 204-545 (1),1 a selective
β1-adrenoceptor antagonist, and discovered it possessed
significant partial agonism. Removal of 1’s aromatic
nitrile afforded 19, a ligand with similar β1-adrenoceptor selectivity and partial agonism (log KD of −7.75 and −5.15 as an antagonist
of functional β1- and β2-mediated
responses, respectively, and 34% of the maximal response of isoprenaline
(β1)). In vitro β-adrenoceptor selectivity
and partial agonism of 19 were mirrored in vivo. We designed
analogues of 19 to improve affinity, selectivity, and
partial agonism. Although partial agonism could not be fully attenuated,
SAR suggests that an extended alkoxyalkoxy side chain, alongside substituents
at the meta- or para-positions of
the phenylurea, increases ligand affinity and β1-selectivity.